Miramel (Pramipexole Dihydrochloride Monohydrate)

Miramel (pramipexole) is used in disorders that involve dopaminergic deficiency or dysfunction.

• Parkinson's disease: improves motor symptoms such as tremor, rigidity and bradykinesia.
• Restless legs syndrome: reduces the urge to move the legs and associated discomfort.
• Parkinson's disease – early motor fluctuations: helps control wearing‑off phenomena and delayed onset dyskinesia.

• Pramipexole is a selective agonist of dopamine D2 and D3 receptors. By binding to these postsynaptic receptors in the basal ganglia and other brain regions, it mimics dopamine activity, enhancing dopaminergic neurotransmission. This compensates for the loss of endogenous dopamine in Parkinsonian pathways and modulates sensory‑motor circuits implicated in restless legs syndrome, with high affinity for D3 receptors contributing to its efficacy.

Pramipexole may cause a range of adverse reactions, which are grouped by frequency and severity.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Dizziness: sensation of light‑headedness, especially on standing.
• Somnolence: increased sleepiness or fatigue.
• Edema: swelling of the lower extremities.

Serious or Rare Side Effects

• Hallucinations: visual or auditory disturbances that may require discontinuation.
• Impulse control disorders: compulsive gambling, shopping or hypersexuality.
• Orthostatic hypotension: marked drop in blood pressure upon standing leading to fainting.

When prescribing Miramel, clinicians should consider several safety measures.

• Renal impairment: dose adjustment may be required in patients with reduced kidney function.
• Cardiovascular disease: monitor for hypotension and arrhythmias, especially in elderly patients.
• Psychiatric history: observe for emergence of hallucinations or impulse control disorders.
• Concomitant CNS depressants: use caution as additive sedation may occur.
• Pregnancy and lactation: avoid use unless benefits outweigh potential risks, as safety data are limited.
• Store at ambient temperature: keep below 25 °C, protect from moisture and light in the original container.

Pramipexole can interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid)

• Antipsychotics (e.g., haloperidol, risperidone): may antagonize dopamine agonist effect.
• MAO‑B inhibitors (e.g., selegiline, rasagiline): combined use can increase risk of hypertensive crisis.
• Strong CYP2D6 inhibitors (e.g., quinidine): may raise pramipexole plasma levels.

Moderate Interactions (Monitor Closely)

• Opioids (e.g., morphine, oxycodone): additive central nervous system depression.
• Alcohol: enhances sedation and dizziness.
• Antihypertensive agents: may potentiate orthostatic hypotension.
• SSRIs or SNRIs: monitor for increased risk of impulse control behaviors.